3 research outputs found
Synthesis of Sugar–Boronic Acid Derivatives: A Class of Potential Agents for Boron Neutron Capture Therapy
To date, sugar analogues
that contain boronic acids as substitutes
for hydroxyl groups are a class of compounds nearly unknown in the
literature. The challenging synthesis of two sugar–boronic
acid analogues is described, and data are retrieved on their solution
behavior, stability, and toxicity. As these compounds were expected
to mimic the behavior of carbohydrates, they were tested in regards
to their future development as potential boron neutron capture therapy
agents
Niosomes as Biocompatible Scaffolds for the Multivalent Presentation of Tumor-Associated Antigens (TACAs) to the Immune System
Fully synthetic tumor-associated carbohydrate antigen
(TACA)-based
vaccines are a promising strategy to treat cancer. To overcome the
intrinsic low immunogenicity of TACAs, the choice of the antigens’
analogues and multivalent presentation have been proved to be successful.
Here, we present the preparation, characterization, and in
vitro screening of niosomes displaying multiple copies of
the mucin antigen TnThr (niosomes-7) or of TnThr mimetic 1 (niosomes-2). Unprecedentedly, structural differences,
likely related to the carbohydrate portions, were observed for the
two colloidal systems. Both niosomal systems are stable, nontoxic
and endowed with promising immunogenic properties
A Synthetic Disaccharide Analogue from Neisseria meningitidis A Capsular Polysaccharide Stimulates Immune Cell Responses and Induces Immunoglobulin G (IgG) Production in Mice When Protein-Conjugated
Some
new phosphonoester-linked oligomers, stabilized analogues of the corresponding
phosphate-bridged oligomers of Neisseria meningitidis A (MenA) capsular polysaccharide (CPS), were conjugated to human
serum albumin (HSA), as a protein carrier model, and studied for
immunological activities. We determined (i) in vitro, their biocompatibility
(CAM test) and activity in inducing both T cell proliferation (CFSE
method) and IL-2 release (ELISA), and (ii) in vivo, their ability
to stimulate specific IgG antibody production (ELISA). All HSA-conjugated
compounds induce T cell proliferation (40% of proliferation at 10<sup>2</sup> ÎĽM), whereas only the phosphonodisaccharide was effective
(28% of proliferation at 10<sup>2</sup> ÎĽM) among the unconjugated
forms. IL-2 release confirmed these results. In addition, the HSA-conjugated
showed in vivo the capacity of eliciting the production of specific
IgG antibodies. In conclusion, we obtained novel biocompatible, water-stable,
and immunoactive MenA CPS analogues. A short disaccharide fragment
showed the unusual behavior of triggering T cell proliferation in
vitro